Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 370 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN016 FOR PRESENTATION AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 79% confidence The document is a voluntary corporate announcement by Alphamab Oncology about clinical research updates and ASCO presentation details. It does not contain financial results, management changes, proxy materials, or formal report attachments. It is a general regulatory announcement/fallback category for miscellaneous company disclosures under Hong Kong Listing Rules. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-06-02 English
VOLUNTARY ANNOUNCEMENT - RESULTS OF PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) FOR NEOADJUVANT TREATMENT OF BC WERE PRESENTED AT LBA ORAL PRESENTATION SESSION OF 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement on the Stock Exchange of Hong Kong about clinical trial results for Anbenitamab. It contains no financial statements, earnings data, management changes, or share transactions – it is simply an operational update. It is not an investor presentation, earnings release, or any other specific filing type. Therefore it falls into the general “Regulatory Filings” category for miscellaneous announcements (RNS).
2026-06-01 English
INSIDE INFORMATION ANNOUNCEMENT - ANBENITAMAB INJECTION OBTAINED MARKETING APPROVAL FROM THE NMPA
Regulatory Filings Classification · 90% confidence The document is an “Inside Information Announcement” made under the Hong Kong Listing Rules (Rule 13.09(2)(a) and Part XIVA of the Securities and Futures Ordinance). It contains regulatory boilerplate (HKEX disclaimer), discloses material corporate information (marketing approval from the NMPA) but does not include financial results, management discussion, or any vote results. It is not a full report (Annual, Interim, ESG, etc.) nor a proxy or meeting material. Therefore it should be classified as a general regulatory announcement (Regulatory Filings).
2026-05-29 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 98% confidence The document is a Next Day Disclosure Return under HKEX Listing Rules detailing changes in issued shares and treasury shares (including issuance of new shares via exercise of options). This constitutes an announcement of a capital change (new share issue). It does not contain full financial statements, nor is it merely announcing an attached report. It is specifically reporting share issuance details. Therefore, it fits the definition of Share Issue/Capital Change (Code: SHA).
2026-05-21 English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 12, 2026
Proxy Solicitation & Information Statement Classification · 92% confidence The document is a Form of Proxy for use at the Annual General Meeting of Alphamab Oncology, providing voting instructions and solicitation of proxies from shareholders. This is part of materials sent to shareholders to request votes for the meeting. Therefore, it fits the definition of Proxy Solicitation & Information Statement.
2026-05-20 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is the formal notice of the Annual General Meeting of Alphamab Oncology, specifying the meeting date, location, agenda items, resolutions to be proposed, proxy and voting procedures, and related administrative details. It does not contain the actual meeting materials or presentations nor the voting results, but rather announces and provides details for the upcoming AGM. Therefore, it is classified as AGM Information.
2026-05-20 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.